PPARG and chronic kidney disease: Overexpression of α-Klotho, on the other hand, abolishes the osteochondrogenic transition of VSMC by downregulating PIT1 and PIT2, effects that were also achieved with PPARγ agonists achieved in CKD mice [111,132,137].